RFK Jr.’s Panel to Evaluate Mercury in Flu Vaccines

RFK Jr.'s Panel to Evaluate Mercury in Flu Vaccines

A newly formed group of advisors, brought together by Robert F. Kennedy Jr., is preparing to cast their votes on the use of thimerosal, a mercury-based preservative, in certain flu vaccines. This preservative, used safely in some flu shots, has been wrongly associated with autism in the past.

The Advisory Committee on Immunization Practices, known as ACIP, is set to discuss and vote on matters concerning vaccines containing thimerosal at a meeting scheduled for June 26. An agenda for this two-day gathering, released on Wednesday, reveals these plans.

New Appointees and the Meeting's Agenda

This meeting marks the first gathering with Kennedy's freshly appointed members, many recognized for their critical stance on vaccines. Kennedy selected these eight advisors last week following a reformation of the committee that provides guidance to the Centers for Disease Control and Prevention regarding vaccine policies.

Specific details of the discussion and the precise nature of the vote are currently not available.

Thimerosal's Role and Usage

Historically used to inhibit bacterial growth in multi-dose vials, thimerosal's application in vaccines has diminished as manufacturers favor single-dose packaging that requires no preservatives.

Nonetheless, certain adult flu vaccines, including Fluzone and two others from CSL Seqirus, still contain thimerosal. The FDA ensures that all routinely recommended vaccines for children up to six years old in the U.S. are available in thimerosal-free forms.

Scientific Perspective on Thimerosal

Prominent health organizations like the FDA underscore that extensive research across more than two decades shows no evidence linking thimerosal to health issues, including neurological or developmental disorders.

According to the FDA, 'The accumulation of scientific data over more than 20 years aligns against claims of harm, including severe neurodevelopmental conditions attributable to thimerosal in vaccines.'

Impact of New Committee Members

The recently appointed ACIP members are expected to influence U.S. immunization policy significantly. The panel's role extends beyond reviewing and making recommendations on who should receive vaccines to determining whether insurance coverage should include them.

The committee's discussions during the meeting will not only focus on thimerosal but will also involve evaluations and decisions on other vaccines, including those for Covid and RSV.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts